2026 Annual General Meeting - MD & CEO's Address
Released
Released
Announcement PDF
Atomo Diagnostics Limited
ACN 142 925 684
Level 1, 3-5 George St Leichhardt NSW 2040
ASX Announcement 5 November 2026
2026 Annual General Meeting – MD & CEO’s Address
In accordance with ASX Listing Rule 3.13.3, Atomo Diagnostics Limited (Atomo) attaches
the MD & CEO’s Address to be delivered at Atomo’s 2026 Annual General Meeting.
For more information, please contact For Media questions, please contact:
Cheri Walker, PhD George Hazim
Atomo Diagnostics Director
cheri.walker@atomodiagnostics.com Media and Public Affairs Australia
Phone: +61 2 9099 4750 georgehazim@mediaaffairs.com.au
Phone: +61417516262
This announcement was authorised by the Managing Director & CEO on behalf of the Board
1
ATOMO
DIAGNOSTICS
FY26 AGM PRESENTATION
5 NOVEMBER 2026
2
This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on
information available as at the date of this presentation. The information in this presentation is
provided in summary form and does not contain all information necessary to make an investment
decision. Reliance should not be placed on the information or opinions contained in this
presentation. An investor must not act on the basis of any matter contained in this presentation
but should make its own assessment of Atomo as part of its own investigations.
This presentation has been provided for general information purposes only. It does not constitute
an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any
security in Atomo, nor does it constitute financial product advice or take into account any
individual’s investment objectives, taxation situation, financial situation or needs.
Although reasonable care has been taken to ensure that the facts stated in this presentation are
accurate and that the opinions expressed are fair and reasonable, no representation or warranty,
express or implied, is made as to the fairness, accuracy, completeness or correctness of the
information, opinions and conclusions contained in this presentation. To the maximum extent
permitted by law, neither Atomo, nor any of its officers, directors, employees and agents, nor any
other person, accepts any responsibility or liability for the content of this presentation including,
without limitation, any liability arising from fault or negligence, for any loss arising from the use of
or reliance on any of the information contained in this presentation or otherwise arising in
connection with it. This disclaimer also extends to all and any information and opinions contained
in, and any omissions from, any other written or oral communications transmitted or otherwise
made available to the recipient in connection with the opportunity outlined in this presentation and
no representation or warranty is made in respect of such information.
The information presented in this presentation is subject to change without notice and Atomo does
not have any responsibility or obligation to inform you of any matter arising or coming to their
notice, after the date of this presentation, which may affect any matter referred to in this
presentation. The cover image is illustrative only.
This presentation may contain certain forward-looking statements that are based on Atomo’s
beliefs, assumptions and expectations and on information currently available to Atomo
management. Such forward looking statements involve known and unknown risks, uncertainties,
and other factors which may cause the actual results or performance of Atomo to be materially
different from the results or performance expressed or implied by such forward looking
statements. Such forward looking statements are based on numerous assumptions regarding
present and future business strategies and the business, economic and competitive environment in
which they operate in the future, which are subject to change without notice. Past performance is
not necessarily a guide to future performance, and no representation or warranty is made as to the
likelihood of achievement or reasonableness of any forward-looking statements or other forecast.
To the full extent permitted by law, Atomo and its directors, officers, employees, advisers, agents
and intermediaries disclaim any obligation or undertaking to release any updates or revisions to
information to reflect any change in any of the information contained in this presentation
(including, but not limited to, any assumptions or expectations set out in the presentation).
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
DISCLAIMER ASX: AT1
OUR MISSION
Put the user experience at the centre of diagnostics—expanding equitable and affordable
access to accurate diagnosis and a seamless pathway to treatment.
HOW WE WORK
IMPACT
Commercialise products that
matter in point-of-care settings.
INNOVATION
Turn creative thinking into
practical solutions.
INTEGRITY
Act with honesty and fairness in
everything we do.
COLLABORATION
Work as one global team.
EXCELLENCE
Be recognised as experts in the
field.
Five values translate Atomo’s purpose into how the company innovates, partners and delivers.
OUR PURPOSE: Empowering healthier lives through fast, accurate, point of care testing
PURPOSE-LED INNOVATION BUILT ON CORE VALUES
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 3
4
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Commercial-stage diagnostics company with a growing pipeline of proprietary and OEM partnerships
WHO IS ATOMO? WHAT BUSINESSES DO WE HAVE?
COMMERCIAL STAGE
DIAGNOSTIC COMPANY with approved
professional and self-test point-of-care products
sold across global markets.
DIFFERENTIATED TECHNOLOGY
Patented all-in-one blood collection solutions
designed for superior usability, reliability and
performance in decentralised testing.
PROVEN COMMERCIAL TRACTION
HIV GEN 3 | +21% FY26 YoY
5m+ tests supplied across 30+ countries.
ATOMO PROPRIETARY PRODUCTS
Blood-based rapid tests sold globally through professional and self-test
channels.
IN MARKET HIV Gen 3 franchise
GROWING PIPELINE Gen 4 HIV · Active Syphilis · Liver / ALT
POINT-OF-CARE TECHNOLOGIES | OEM
Integrated all-in-one and modular devices that help partners improve the usability
and performance of blood-based tests.
FEBRIDX®
DRIVES GROWTH
OEM revenue +209% FY26 YoY | 215 live US sites in Q1FY27
PARTNER PIPELINE Pregnancy commercial · Ferritin and pre-hospital stroke in
validation
WHO IS ATOMO AND WHAT DO WE DO?
5
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
SOLUTIONS THAT DELIVER
Issues with Standard Multi-Component Test Kits Advantages of Atomo Devices
Initial solutions focused on transforming usability in the lateral flow market
Next generation POCT devices that provide superior usability and performance
6
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Future of Point of Care & Rapid Testing [8]
EASY TO USE
SPEED OF RESULTS
EASY TO OBTAIN & AFFORDABLE
Simple to use products providing reliability and usability
in decentralised settings
Rapid results with a high degree of accuracy
Accessibility online and increasingly through retail and
via healthcare professionals
Report - Comparative usability analysis of two rapid diagnostic self-test kits [9]
ASX: AT1
Focus on ease of use, speed of results and affordability ASX: A1
ATOMO PLATFORM DRIVING ADOPTION OF RAPID TESTING
7
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Each platform simplifies capillary blood collection and delivery; the key difference is how it integrates with the test cassette.
PASCAL
Integrated all-in-one platform
MOST INTEGRATED CONFIGURATION
• Built-in, auto-retracting safety lancet
• Precise button-activated buffer delivery
• Interlocked steps help reduce user error
• 99% concordance between professional and non-
professional users
PRIMARY FIT
POINT OF CARE + SELF-TEST
GALILEO
Streamlined all-in-one platform
SIMPLIFIED BLOOD HANDLING
• Built-in, auto-retracting safety lancet
• Precise blood collection and delivery
• Patient-delivered buffer creates assay flexibility
PRIMARY FIT
POINT OF CARE + SELF-TEST
FLOREY
Modular clip-on usability upgrade
LOW-DISRUPTION CASSETTE UPGRADE
• Clips onto an existing blood-based cassette
• Adds precise button-activated buffer delivery
• Cassette remains readable by a validated reader
PRIMARY FIT
EXISTING COMMERCIAL TESTS
SOLUTIONS THAT DELIVER
Atomo offers three blood-based platforms driven by the market requirements
7
8
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
ASX: AT1
Atomo’s audited QMS supports registrations achieved directly and with partners ASX: A1
GLOBAL QUALITY & REGULATORY STRENGTH
QUALITY FOUNDATION
External scrutiny
Regularly audited by multiple tier-one national regulators
and the World Health Organization.
Measurable quality objectives
Business and product objectives are set at the levels
required to meet product requirements.
IVDR-ready governance
QMS compliant with IVDR requirements for Class III and IV
products.
CERTIFICATES & REGULATORY EVIDENCE
GLOBAL REGULATORY FOOTPRINT
ATOMO — LISTED MANUFACTURER
HIV SELF TEST
TGA · Australia
WHO PQ · LMIC | CE Mark · UK & Europe
PARTNER REGISTRATIONS
PREGNANCY TEST
CE Mark · UK & Europe | ANVISA · Brazil
LUMOS DIAGNOSTICS’ FEBRIDX
FDA 510(k) + CLIA waiver · USA
CE Mark · UK & Europe | TGA · Australia
Health Canada · Canada
TGA WHO PQ FDA CE MARK ANVISA HEALTH CANADA
BSI / QMS TGA WHO PQ CE SAHPRA
FUTURE FOCUS
• MDSAP
• ACTIVE SYPHILIS — TGA / IVDR
• GEN 4 HIV — TGA / IVDR
SYPHILIS / GEN 4 HIV – Future Filings
TGA · Australia
CE Mark · UK & Europe
9
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
TWO PROVEN ENGINES FOR COMMERCIAL GROWTH
Commercial-stage diagnostics company pairing an established HIV franchise with a proven OEM platform
ATOMO PROPRIETARY PRODUCT FRANCHISE
+21%
FY26 HIV SALES GROWTH | YOY
HIV GEN 3 DEMONSTRATES ATOMO’S ABILITY TO
BUILD AND SCALE ITS OWN PRODUCTS
5m+ tests supplied across 30+ countries, with growth led by
international supply and ANZ pharmacy channels.
OEM PARTNERSHIP BUSINESS
+209%
FY26 OEM REVENUE GROWTH | YOY
FEBRIDX® SHOWS THE POWER OF THE OEM
PARTNERSHIP MODEL
Device supply increased 224% in 1Q27 YOY.
Proven and growing revenue bases validate the two scalable paths to diversified growth
ASX: AT1
Commercial products fund a broader portfolio progressing through validation, development and feasibility
ATOMO PROPRIETARY PRODUCT PIPELINE ASX: AT1
Proprietary portfolio spans established revenue products and new tests targeting decentralised professional and self-test markets.
PRODUCT / APPLICATION
FEASIBILITY
STUDY
DEVELOPMENT VALIDATION COMMERCIAL
HIV GEN 3 HIV screening / self-test
COMMERCIAL
HIV GEN 4 Antibody + p24 antigen
DEVELOPMENT
ACTIVE SYPHILIS Active vs treated infection
VALIDATION
LIVER / ALT Liver health screening
DEVELOPMENT
HCV Hepatitis C virus
FEASIBILITY
HBV Hepatitis B virus
FEASIBILITY
10
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
OVERVIEW OF ATOMO'S GEN 3 HIV SELF-TEST ASX: AT1
Integrated, highly accurate self-testing platform with established market adoption and expanding retail and public-health channels
11
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
TEST DIFFERENTIATION
15 MINUTES
Integrated, blood-based rapid
diagnostic test designed for
convenient, private and discreet self-
testing.
SIMPLIFIES THE USER JOURNEY
All-in-one components and
interlocked steps reduce
procedural complexity and help
mitigate common user errors.
PRODUCT + MARKET PROOF
99.6%
SENSITIVITY
identifies HIV-positive
samples
99.6%
SPECIFICITY
identifies HIV-negative
samples
5M+
TESTS SUPPLIED
to markets across more
than 30 countries
Performance published by Atomo; reach and supply
figures from company materials.
COMMERCIAL MOMENTUM
AUSTRALIAN MARKET LEADER
Across public and private channels, supported
by national mail-out and vending-machine
programs.
RETAIL EXPANSION
Chemist Warehouse in Australia and New
Zealand, plus Tesco and Boots in the UK.
PUBLIC-HEALTH PROCUREMENT
Free-to-user access programs and government
purchasing are emerging as long-term growth
drivers.
ACTIVE SYPHILIS TRANSFERS TO MANUFACTURING ASX: AT1
Program remains on schedule, with regulator engagement beginning and launch targeted within 18–24 months
12
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
TEST DIFFERENTIATION
15 MINUTES
Rapid lateral flow test for home-
based and healthcare-practitioner-
guided self-testing.
ADDRESSES A KEY TESTING GAP
Designed to detect infectious
syphilis and distinguish active
cases from previously treated
cases.
EARLY CLINICAL PERFORMANCE
100%
SENSITIVITY
against active syphilis
samples by clinical history
99%
SPECIFICITY
against never-infected
patients
93%
SPECIFICITY
against previously treated
cases with clinical history
Early clinical testing; results reported by clinical
history.
PROGRAM ON SCHEDULE
TRANSFER COMPLETE
Test-strip manufacturing moved from Burnet
Institute in Melbourne to Cape Town for clinical-
trial production builds.
NEXT: CLINICAL TRIALS
Trials expected to commence early next year.
REGULATORY + LAUNCH
Engagement planned with TGA, FDA and BSI;
commercial launch targeted within 18–24
months.
ASX: AT1
Global licence, development and supply agreement with Innovation Scientific
GEN 4 HIV PARTNERSHIP OPENS A NEW COMMERCIAL PATH
ASX: AT1
THE MOU AGREEMENT
Atomo to receive a
global licence to
commercialise a rapid
Gen 4 HIV assay in its
Galileo cassette.
Feasibility testing complete. The
partnership now moves into
final analytical/clinical studies and
regulatory preparation.
Parties to negotiate final Supply
Agreement and License over next
four months.
WHO DOES WHAT
INNOVATION SCIENTIFIC
— Complete final assay development
— Run analytical and clinical studies with Atomo
— Integrate Galileo sub-assemblies with the strip and
buffer for finished supply
ATOMO
— Hold the global assay licence and act as legal
manufacturer
— Lead IVDR and TGA registration, launch and
commercialisation
COMMERCIAL PATH
18 MONTHS
Planned IVDR and TGA registration window
24 MONTHS
Target timing for commercial launch
A$1.16bn
HIV global rapid-test kit market
STRATEGIC FIT Extends Atomo’s Gen 3 HIV + Active Syphilis portfolio; own-pipeline revenue is targeted from late FY2028.
Manufacture and supply Galileo sub-assemblies
—
Source: Future Market Insights, 2026; Market Glass, Inc., 2026;
MarketsandMarkets, 2025
13
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
ALT LIVER TEST: LIVER-INJURY INSIGHT AT THE POINT OF CARE ASX: AT1
A proven ALT assay on Atomo’s Pascal platform creates multiple clinical, pharmaceutical and public-health pathways
14
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
TEST PROPOSITION
ALT
A key marker of liver damage used in
diagnosis, treatment evaluation and
disease monitoring.
DECENTRALISED TESTING
Fingerstick blood testing on the
Pascal platform enables rapid liver-
injury assessment at point of care
and at home.
DEVELOPMENT + PERFORMANCE
WORLDWIDE LICENCE
Burnet Institute assay; Atomo is the listed
manufacturer and finished-test supplier
Development is substantially complete;
diagnostic performance has been established.
BROAD COMMERCIAL UTILITY
DILI MONITORING
Pharmaceutical and clinical-trial monitoring for
drug-induced liver injury.
HEPATITIS MANAGEMENT
Supports treatment decisions and ongoing
monitoring in hepatitis B and C.
LIVER-DISEASE SCREENING
Potential screening pathways in fatty-liver and
alcohol-related liver disease.
Test shows good correlation (R2 = 0.9089) between
fingerprick blood and venous blood
The validation set gave AUC 0.94 performance
distinguishing normal from abnormal ALT at 40 IU/L
PERFORMANCE
ASX: AT1
Atomo technology enables partner assays to move from technical validation into commercial supply at scale
OEM PARTNER PIPELINE ASX: AT1
OEM pipeline focused on professional point-of-care markets and scalable partner supply.
PRODUCT / APPLICATION
FEASIBILITY DEVELOPMENT VALIDATION COMMERCIAL
FEBRIDX® Lumos · acute respiratory
infection
COMMERCIAL
FERRITIN Chromacare · iron deficiency
VALIDATION
BRAIN DISEASE Upfront · pre-hospital triage
VALIDATION
Atomo technology platforms support multiple partner assays—creating recurring device-supply opportunities as programs progress.
PREGNANCY NG Biotech · early pregnancy
detection
COMMERCIAL
15
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
ASX: AT1
FEBRIDX®: FINGERSTICK TO 10-MINUTE ANTIBIOTIC DECISION AID
ASX: AT1
Lumos’ CLIA-waived test combines dual host-response biomarkers with Atomo’s integrated Pascal platform
RAPID RESPIRATORY TRIAGE
A rapid, instrument-free point-of-care test
that helps distinguish bacterial infection from
non-bacterial causes—supporting more
confident antibiotic decisions.
PRODUCT + COMMERCIAL OVERVIEW
FebriDx pairs Lumos’ MxA + CRP host-response assay with
Atomo’s Pascal cassette for a simple, portable fingerstick
workflow.
DIFFERENTIATE
Dual MxA + CRP
biomarkers help
separate bacterial
infection from non-
bacterial etiology.
DECIDE IN 10
A visual result after 10
minutes supports
treatment decisions
during the initial visit.
SCALE IN THE US
FDA CLIA waiver enables
use at waived sites; Pascal
delivered >99%
trained/untrained
concordance.
A$1.9m FY26 Atomo FebriDx orders—approximately 9×
FY25—supporting recurring Pascal demand.
16
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
ATOMO OEM PERFORMANCE | FY26 YEAR-ON-YEAR
+209%
OEM SALES REVENUE
+224%
GROWTH IN DEVICES SUPPLIED
US FEBRIDX® ADOPTION | LUMOS-REPORTED
215 LIVE US SITES
September 2026
+26.5% 170 in July → 215 in September
405 sites under evaluation (350 in July)
March 2026 FDA CLIA waiver expanded eligible US testing settings.
OEM Momentum Flu-season inventory build fuels triple-digit revenue and device-volume growth.
Strong YOY growth driven by Lumos Diagnostics’ FebriDx
PASCAL OEM REVENUE PERFORMANCE ASX: AT1
17
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
ASX: AT1
TWO BLOOD-BASED TESTS EXPAND PASCAL PLATFORM ASX: AT1
NG Biotech pregnancy and Chromacare ferritin programs pair partner assays with an integrated fingerstick
Sources: NG Biotech Professional Tests and Self-Tests; Chromacare Labs ferritin test; Atomo Diagnostics Pascal and partner materials. Accessed 23 Oct 2026.
NG BIOTECH | BLOOD PREGNANCY CHROMACARE | FERRITIN
NG Biotech’s hCG assay and Atomo’s all-in-one Pascal
platform support both professional and self-testing
settings.
Chromacare’s quantitative ferritin assay is being
integrated into Pascal for professional and at-home iron-
deficiency testing.
5 MIN
QUALITATIVE RESULT
10 µL
FINGERSTICK SAMPLE
10 mIU/mL
DETECTION LIMIT
NG Biotech reports 100% sensitivity and
specificity.
10 MIN
QUANTITATIVE RESULT
APP-GUIDED
READ, STORE + TRACK
PASCAL
INTEGRATED BLOOD HANDLING
Results can be tracked over time and shared with
healthcare providers.
2 routes to market: professional testing + NG PRECISION+
consumer self-test. A$170k initial order supports product validation and
regulatory registration.
18
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
ASX: AT1
Upfront’s biomarker assay moves into Atomo’s technology platform
UPFRONT + ATOMO PARTNER ON NEXT-GENERATION TEST ASX: AT1
LVTwo
A rapid blood-based brain-disease test
designed for use before hospital arrival—
helping emergency teams triage suspected
stroke or other brain-disease patients
sooner.
PARTNERSHIP ANNOUNCEMENT
Atomo and Upfront announce partnership for Upfront’s
next-generation test in Atomo’s device.
DETECT
Proprietary biomarker
targets proteins associated
with brain disease.
DEPLOY
Atomo hand-held devices
combine blood collection,
sample transfer and buffer
delivery.
DECIDE EARLIER
Designed for pre-hospital
use to support faster
routing and treatment
decisions.
9,000
Atomo sub-assemblies supplied for validation and
verification activities to date
19
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
FY 2026 FINANCIALS
21
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
FY26 – PROFIT & LOSS
AUD
FY26
($m)
FY25
($m)
(%)
Revenue 5.33 3.79 41%
Cost of sales (3.45) (1.87)
Gross Profit 1.88 1.92 (2%)
Gross Margin 35% 51%
Other income 2.24 1.52 47%
Employee benefits expense (2.88) (3.26) 12%
Foreign exchanges gains/(losses) (0.04) (0.01) (300%)
Research and development costs (0.76) (0.62) (23%)
Professional fees expense (0.49) (0.95) 48%
Inventory obsolescence expense (0.12) (0.13) 8%
Other expenses (1.89) (1.85) (2%)
Underlying EBITDA (2.06) (3.38) 39%
Revenue grew strongly and the underlying EBITDA loss narrowed by 39%
* Amounts in A$m; YoY compares FY26 with FY25
REVENUE
$5.33m
FY25 $3.79m
+41% YoY
GROSS MARGIN
35%
FY25 51%
-16 pts YoY
UNDERLYING EBITDA
($2.06m)
FY25 ($3.38m)
39% improvement
22
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
FY26 – BALANCE SHEET
AUD
FY26
($m)
FY25
($m)
Cash and cash equivalents 3.71 3.22
Trade and other receivables 3.22 1.69
Inventories 1.97 1.65
Property, plant and equipment 0.34 0.89
Intangible assets 1.22 1.64
Other assets 0.36 0.18
Total assets 10.82 9.27
Trade and other payables 1.68 1.02
Other liabilities 1.43 1.28
Total liabilities 3.11 2.30
Net Assets 7.71 6.97
FY26 closed with $3.71m in cash, $10.66m in assets and no bank debt
* Amounts in A$m; June 2026 audited actuals
CASH
$3.71m
available liquidity
TOTAL ASSETS
$10.66m
at June 2026
NO DEBT
$0
bank borrowings
23
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
FY26 CASHFLOW
A$m
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
Strong cash generation from sales, grants, and fundraising activities
TOTAL CASH RECEIPTS
$10.2m
$4.6m customer receipts
plus R&D rebate, CRC-P grant and capital
TOTAL CASH PAYMENTS
$9.7m
$4.1m stock purchases
$5.6m operating expenses
YEAR-END CASH
$3.7m
at 30 June 2026
no debt
Revenue
Operating
Discipline
EBITDA
Productive
Assets
FY25 Revenue
A$3.8M
✓ Atomo is seeing strong momentum in its established revenue
channels including HIV Testing and Pascal OEM
✓ Expansion of customer base across new partners for Pascal and
an expanded Atomo test product pipeline
FY26 Revenue A$5.3M
+40% GROWTH
✓ Capital focus on new test portfolio
development / commercialisation – Syphilis and
Liver
✓ Non-dilutive funding grants (Syphilis) and
selective licensing of proven assets (Liver) used
to support lower-cost development and go to
market
-5
-4.5
-4
-3.5
-3
-2.5
-2
-1.5
-1
-0.5
0
FY24 FY25 FY26
A$(m)
Historical EBITDA
✓ EBITDA – continued trend towards breakeven
as existing revenue channels grow and
product offerings expand
✓ Debt free balance sheet
✓ Atomo validating a second-generation
blister machine and high-cavity mould
tooling to support expansion of capacity
and improve economies of scale and
margins
ASX: AT1
FINANCIAL SUMMARY
24
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
FY2026 was a transitional year, showing strong and sustainable revenue growth with improving EBITDA
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 25
FY26
Scale the core.
Improve the margins.
Expand the pipeline.
Atomo’s priorities align commercial
growth with manufacturing scale,
disciplined cash management and
the development of new finished
tests.
Point-of-care and self-testing solutions
designed around simple, integrated
blood collection.
01 HIV MARKET EXPANSION
Grow established sales channels and secure new territory distribution partners.
02 PORTFOLIO EXPANSION
Advance finished tests beyond HIV, including Liver and blood pregnancy opportunities.
03 SYPHILIS & GEN 4 HIV DEVELOPMENT
Progress clinical and regulatory work for syphilis and Gen 4 HIV.
04 OPERATIONS & MARGINS
Scale Pascal output and improve margins through in-housing and economies of scale.
05 CASH DISCIPLINE
Maintain close control of operating costs and the use of cash.
06 PLATFORM ADOPTION
Add Pascal OEM customers and progress Florey with an initial customer.
STRATEGIC IMPERATIVES FOR FY2027
Executing priorities focused on revenue growth, portfolio expansion, and scalable operations
26
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
BUILDING A STRONGER BASE FOR SCALABLE GROWTH
Commercial momentum is funding a broader product pipeline and a more diversified revenue base
$5.33m
FY26 REVENUE | +41% YoY
HIV franchise +21% YoY
OEM revenue +209% YoY
HIV FRANCHISE LEADS COMMERCIAL TRACTION
HIV sales increased 21% year on year, led by international supply and ANZ
pharmacy and public health channels.
FEBRIDX® SHOWS THE POWER OF THE OEM MODEL
OEM revenue reached $2.2m, up 209% year on year, while device supply
increased 224%.
DIVERSIFICATION BUILDS OVER TIME
Commercial HIV, pregnancy, and FebriDx® provide the commercial base
as the proprietary pipeline and OEM programs in syphilis, Gen 4 HIV,
stroke, ferritin, and earlier-stage assays advance.
A stronger HIV franchise and scalable OEM model support a broader, more diversified growth platform over time.
Share your feedback
Discover